![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWXc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--8f2343b9ecd1cc61e4fa6eb683732f4f7077c36f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/CytomX-1.png)
CytomX
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on our Probody™ technology platform.
Website
cytomx.comPartner
Tim ShannonInvestment
Series B
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on our Probody™ technology platform.
Series B